Dynamics of 8G12 competitive antibody in “prime-boost” vaccination of Hepatitis E vaccine

References

• Tam AW, Smith MM, Guerra ME, Huang CC, Bradley DW, Fry KE, Reyes GR. Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome. Virology 1991; 185:120-31; PMID:1926770; https://doi.org/10.1016/0042-6822(91)90760-9
   PubMed Web of Science ®Google Scholar
• Aggarwal R. The global prevalence of hepatitis E virus infection and susceptibility: a systematic review. Geneva, Switzerland, World Health Organization 2010
   Google Scholar
• Khuroo MS, Teli MR, Skidmore S, Sofi MA, Khuroo MI. Incidence and severity of viral hepatitis in pregnancy. Am J Med 1981; 70:252-5; PMID:6781338; https://doi.org/10.1016/0002-9343(81)90758-0
   PubMed Web of Science ®Google Scholar
• Kumar A, Beniwal M, Kar P, Sharma JB, Murthy NS. Hepatitis E in pregnancy. Int J Gynaecol Obstet 2004; 85:240-4; PMID:15145258; https://doi.org/10.1016/j.ijgo.2003.11.018
   PubMed Web of Science ®Google Scholar
• Khaskheli MN, Baloch S, Sheeba A. Acute Hepatitis E Viral infection in pregnancy and maternal morbidity. J Coll Physicians Surg Pak 2015; 25:734-7; PMID:26454389
   PubMed Web of Science ®Google Scholar
• Emerson SU, Nguyen H, Graff J, Stephany DA, Brockington A, Purcell RH. In vitro replication of hepatitis E virus (HEV) genomes and of an HEV replicon expressing green fluorescent protein. J Virol 2004; 78:4838-46; PMID:15078965; https://doi.org/10.1128/JVI.78.9.4838-4846.2004
   PubMed Web of Science ®Google Scholar
• Emerson SU, Nguyen H, Torian U, Purcell RH. ORF3 protein of hepatitis E virus is not required for replication, virion assembly, or infection of hepatoma cells in vitro. J Virol 2006; 80:10457-64; PMID:16928762; https://doi.org/10.1128/JVI.00892-06
   PubMed Web of Science ®Google Scholar
• Helsen N, Debing Y, Paeshuyse J, Dallmeier K, Boon R, Coll M, Sancho-Bru P, Claes C, Neyts J, Verfaillie CM. Stem cell-derived hepatocytes: A novel model for hepatitis E virus replication. J Hepatol 2016; 64:565-73; PMID:26626494; https://doi.org/10.1016/j.jhep.2015.11.013
   PubMed Web of Science ®Google Scholar
• Okamoto H. Efficient cell culture systems for hepatitis E virus strains in feces and circulating blood. Rev Med Virol 2011; 21:18-31; PMID:21294213; https://doi.org/10.1002/rmv.678
   PubMed Web of Science ®Google Scholar
• Purdy MA, McCaustland KA, Krawczynski K, Spelbring J, Reyes GR, Bradley DW. Preliminary evidence that a trpE-HEV fusion protein protects cynomolgus macaques against challenge with wild-type hepatitis E virus (HEV). J Med Virol 1993; 41:90-4; PMID:8228944; https://doi.org/10.1002/jmv.1890410118
   PubMed Web of Science ®Google Scholar
• Tsarev SA, Tsareva TS, Emerson SU, Govindarajan S, Shapiro M, Gerin JL, Purcell RH. Successful passive and active immunization of cynomolgus monkeys against hepatitis E. Proc Natl Acad Sci U S A 1994; 91:10198-202; PMID:7937861; https://doi.org/10.1073/pnas.91.21.10198
   PubMed Web of Science ®Google Scholar
• Tsarev SA, Tsareva TS, Emerson SU, Govindarajan S, Shapiro M, Gerin JL, Purcell RH. Recombinant vaccine against hepatitis E: dose response and protection against heterologous challenge. Vaccine 1997; 15:1834-8; PMID:9413090; https://doi.org/10.1016/S0264-410X(97)00145-X
   PubMed Web of Science ®Google Scholar
• Li SW, Zhang J, Li YM, Ou SH, Huang GY, He ZQ, Ge SX, Xian YL, Pang SQ, Ng MH, et al. A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. Vaccine 2005; 23:2893-901; PMID:15780738; https://doi.org/10.1016/j.vaccine.2004.11.064
   PubMed Web of Science ®Google Scholar
• Shrestha MP, Scott RM, Joshi DM, Mammen MP, Jr., Thapa GB, Thapa N, Myint KS, Fourneau M, Kuschner RA, Shrestha SK, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007; 356:895-903; PMID:17329696; https://doi.org/10.1056/NEJMoa061847
   PubMed Web of Science ®Google Scholar
• Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, Yang CL, Jiang HM, Cai JP, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376:895-902; PMID:20728932; https://doi.org/10.1016/S0140-6736(10)61030-6
   PubMed Web of Science ®Google Scholar
• Li TC, Yamakawa Y, Suzuki K, Tatsumi M, Razak MA, Uchida T, Takeda N, Miyamura T. Expression and self-assembly of empty virus-like particles of hepatitis E virus. J Virol 1997; 71:7207-13; PMID:9311793
   PubMed Web of Science ®Google Scholar
• Xing L, Kato K, Li T, Takeda N, Miyamura T, Hammar L, Cheng RH. Recombinant hepatitis E capsid protein self-assembles into a dual-domain T = 1 particle presenting native virus epitopes. Virology 1999; 265:35-45; PMID:10603315; https://doi.org/10.1006/viro.1999.0005
   PubMed Web of Science ®Google Scholar
• Li S, Tang X, Seetharaman J, Yang C, Gu Y, Zhang J, Du H, Shih JW, Hew CL, Sivaraman J, et al. Dimerization of hepatitis E virus capsid protein E2s domain is essential for virus-host interaction. PLoS Pathogens 2009; 5:e1000537; PMID:19662165; https://doi.org/10.1371/journal.ppat.1000537
   PubMed Web of Science ®Google Scholar
• Khudyakov Yu E, Favorov MO, Jue DL, Hine TK, Fields HA. Immunodominant antigenic regions in a structural protein of the hepatitis E virus. Virology 1994; 198:390-3; PMID:8259678; https://doi.org/10.1006/viro.1994.1048
   PubMed Web of Science ®Google Scholar
• Schofield DJ, Glamann J, Emerson SU, Purcell RH. Identification by phage display and characterization of two neutralizing chimpanzee monoclonal antibodies to the hepatitis E virus capsid protein. J Virol 2000; 74:5548-55; PMID:10823861; https://doi.org/10.1128/JVI.74.12.5548-5555.2000
   PubMed Web of Science ®Google Scholar
• Meng J, Dai X, Chang JC, Lopareva E, Pillot J, Fields HA, Khudyakov YE. Identification and characterization of the neutralization epitope(s) of the hepatitis E virus. Virology 2001; 288:203-11; PMID:11601892; https://doi.org/10.1006/viro.2001.1093
   PubMed Web of Science ®Google Scholar
• Zhao M, Li XJ, Tang ZM, Yang F, Wang SL, Cai W, Zhang K, Xia NS, Zheng ZZ. A comprehensive study of neutralizing antigenic sites on the hepatitis E virus (HEV) capsid by constructing, clustering, and characterizing a tool box. J Biol Chem 2015; 290:19910-22; PMID:26085097; https://doi.org/10.1074/jbc.M115.649764
   PubMed Web of Science ®Google Scholar
• Zhang J, Gu Y, Ge SX, Li SW, He ZQ, Huang GY, Zhuang H, Ng MH, Xia NS. Analysis of hepatitis E virus neutralization sites using monoclonal antibodies directed against a virus capsid protein. Vaccine 2005; 23:2881-92; PMID:15780737; https://doi.org/10.1016/j.vaccine.2004.11.065
   PubMed Web of Science ®Google Scholar
• He J, Kuschner RA, Dewar V, Voet P, Asher LV, Vaughn DW. Characterization of monoclonal antibodies to hepatitis E virus (HEV) capsid protein and identification of binding activity. J Biomed Sci 2007; 14:555-63; PMID:17487571; https://doi.org/10.1007/s11373-007-9172-4
   PubMed Web of Science ®Google Scholar
• Schofield DJ, Purcell RH, Nguyen HT, Emerson SU. Monoclonal antibodies that neutralize HEV recognize an antigenic site at the carboxyterminus of an ORF2 protein vaccine. Vaccine 2003; 22:257-67; PMID:14615154; https://doi.org/10.1016/j.vaccine.2003.07.008
   PubMed Web of Science ®Google Scholar
• Tang X, Yang C, Gu Y, Song C, Zhang X, Wang Y, Zhang J, Hew CL, Li S, Xia N, et al. Structural basis for the neutralization and genotype specificity of hepatitis E virus. Proc Natl Acad Sci U S A 2011; 108:10266-71; PMID:21642534; https://doi.org/10.1073/pnas.1101309108
   PubMed Web of Science ®Google Scholar
• Gu Y, Tang X, Zhang X, Song C, Zheng M, Wang K, Zhang J, Ng MH, Hew CL, Li S, et al. Structural basis for the neutralization of hepatitis E virus by a cross-genotype antibody. Cell Res 2015; 25:604-20; PMID:25793314; https://doi.org/10.1038/cr.2015.34
   PubMed Web of Science ®Google Scholar
• Lin HJ WX, Gao F, Chen P, Hao XT, Zhou X, Liang ZL. Development and application of a quantitative method in detection of mouse anti-HEV IgG. Prog Microbiol Immunol 2016; 44:17-20
   Google Scholar
• Xing L, Li TC, Mayazaki N, Simon MN, Wall JS, Moore M, Wang CY, Takeda N, Wakita T, Miyamura T, et al. Structure of hepatitis E virion-sized particle reveals an RNA-dependent viral assembly pathway. J Biol Chem 2010; 285:33175-83; PMID:20720013; https://doi.org/10.1074/jbc.M110.106336
   PubMed Web of Science ®Google Scholar
• Meng J, Dubreuil P, Pillot J. A new PCR-based seroneutralization assay in cell culture for diagnosis of hepatitis E. J Clin Microbiol 1997; 35:1373-7. PMID:9163446
   PubMed Web of Science ®Google Scholar
• IMpact-RSV. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998; 102:531-7
   Web of Science ®Google Scholar
• Glenn GM, Fries LF, Thomas DN, Smith G, Kpamegan E, Lu H, Flyer D, Jani D, Hickman SP, Piedra PA. A Randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. J Infect Dis 2016; 213:411-22; PMID:26259809; https://doi.org/10.1093/infdis/jiv406
   PubMed Web of Science ®Google Scholar
• Smith G, Raghunandan R, Wu Y, Liu Y, Massare M, Nathan M, Zhou B, Lu H, Boddapati S, Li J, et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PloS One 2012; 7:e50852; PMID:23226404; https://doi.org/10.1371/journal.pone.0050852
   PubMed Web of Science ®Google Scholar
• Raghunandan R, Lu H, Zhou B, Xabier MG, Massare MJ, Flyer DC, Fries LF, Smith GE, Glenn GM. An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization. Vaccine 2014; 32:6485-92; PMID:25269094; https://doi.org/10.1016/j.vaccine.2014.09.030
   PubMed Web of Science ®Google Scholar